| Literature DB >> 36262423 |
Ural Mukhametov1, Sergey Lyulin2, Dmitry Borzunov3, Tatiana Ilyasova4, Ilgiz Gareev5, Albert Sufianov5,6.
Abstract
Purpose: It is now known that traumatic injury initiates a complex and dynamic immune response on the first day. It is believed that in patients with polytrauma, these immune responses contribute to the development of infectious complications. Therefore, understanding the immune response to trauma is critical to improving patient outcomes through the development of new therapies and improved resuscitation strategies. The purpose of this study is to examine the parameters of immunity in patients with severe polytrauma at the stages of surgical treatment (the nearest post-traumatic period and long-term periods) in the absence and presence of purulent-inflammatory complications.Entities:
Keywords: Biomarker; Cytokines; Immune response; Infectious complications; Polytrauma
Year: 2022 PMID: 36262423 PMCID: PMC9562442 DOI: 10.1016/j.ncrna.2022.09.007
Source DB: PubMed Journal: Noncoding RNA Res ISSN: 2468-0540
Polytrauma cohort baseline characteristics of enrolled patients.
| Characteristics | Patients (n = 188) |
|---|---|
| Median age, years | 31 (IQR 23–55) |
| Sex | |
| Male, n | 122 |
| Female, n | 66 |
| Positive BAL, n | 48 |
| Median ISS | 20 |
| Purulent-inflammatory complications, n | 76 |
| Pneumonia, n | 33 |
| Mechanism of trauma, n | |
| Road transport incidents | 80 |
| Falls from heights | 39 |
| Falling objects | 35 |
| Sports | 16 |
| Сriminal | 8 |
Abbreviations: BAL, blood alcohol level; IQR, interquartile range; ISS, illness severity score.
Clinical parameters of polytrauma patients with complications.
| Characteristics | Purulent-inflammatory complications (n = 76) | Pneumonia (n = 33) |
|---|---|---|
| Median age, years | 31.0 ± 3.63 | 31.0 ± 4,57 |
| Male, n | 44 | 11 |
| Female, n | 32 | 22 |
| Damage localization | ||
| LBF + TBI +CI | 13 | 4 |
| LBF + TBI + CI + spinal injury | 2 | 2 |
| LBF + TBI +CI + pelvic bone injury | 5 | 1 |
| LBF + TBI +CI + abdominal injury | 6 | 12 |
| LBF + TBI + spinal injury + pelvic bone injury | 26 | 0 |
| LBF +CI + spinal injury | 7 | 6 |
| LBF +CI + spinal injury | 4 | 3 |
| LBF +CI + pelvic bone injury | 13 | 5 |
LBF, Long bone fractures; TBI, Traumatic brain injury; CI, Chest injury.
Parameters of cellular immunity in patients after severely injured trauma at the stages of treatment.
| Period | СD3+СD19-% | СD3+СD4+ | СD3+СD8+ |
|---|---|---|---|
| 1 day | 71.4+ (58.0–76.0) | 42.0+ (27.1–43.1) | 26.1 (18.7–31.2) |
| 3 day | 72.9+ (58.7–79.6) | 47.8* (39.0–51.2) | 22.8+ (17.1–30.2) |
| 7 day | 73.5* (68.0–83.0) | 46.7* (40.8–53.6) | 25.1 (17.8–31.4) |
| 14 day | 75.6* (73.1–82.2) | 49.6* (42.0–55.2) | 24.4 (19.1–30.6) |
| 21 day | 80.6* (71.8–85.0) | 48.7* (43.3–56.0) | 25.3 (21.3–33.3) |
| 30 day | 76.0* (71.5–81.3) | 47.1** (44.8–55.1) | 28.3 (21.4–31.4) |
| 60 day | 81.2+* (75.8–85.1) | 44.5* (42.0–47.8) | 33.3+* (26.0–39.0) |
| 90 day | 81.7* (70.8–83.9) | 44.7* (36.3–50.0) | 31.8* (25.0–38.2) |
| Control group | 76.0 (73.4–78.7) | 49.8 (41.0–53.3) | 25.2 (23.3–33.5) |
Note: * (р ≤ 0.05) and ** (р ≤ 0.01), in comparison with indicators of 1 day; + (р ≤ 0.05), in comparison with the indicators of the control group.
T lymphocyte activation markers in patients after severely injured trauma at the stages of treatment.
| Period | СD3+ СD25+ | СD3+HLADR |
|---|---|---|
| 1 day | 9.7+ (7.4–14.0) | 6.4+ (4.1–9.2) |
| 3 day | 6.9+ (6.3–11.3) | 5.6+ (4.1–7.7) |
| 7 day | 9.8+ (7.8–11.9) | 5.5+ (4.0–8.0) |
| 14 day | 8.4+ (6.3–14.0) | 7.1+ (5.2–10.1) |
| 21 day | 9.1+ (8.1–10.5) | 9.2+ (5.8–13.0) |
| 30 day | 7.4+* (5.5–10.2) | 8.2+ (5.0–17.5) |
| 60 day | 4.5+* (4.0–6.6) | 11.0+ (5.7–15.0) |
| 90 day | 4.0* (3.8–4.4) | 8.4+ (5.1–9.2) |
| Control group | 3.2 (2.7–4.3) | 3.2 (2.1–4.0) |
Note: * (р ≤ 0.05), in comparison with indicators of 1 day; + (р ≤ 0.05), in comparison with the indicators of the control group.
Fig. 1The level of B lymphocytes (A) and cytokines/chemokines (B–D) in patients after severely injured trauma at the stages of treatment. Statistical significance (*p ≤ 0.05 and **p ≤ 0.01). Note: Only the indicators of the 1 day were compared with those of the control group. The indicators of the rest days were compared with the indicators of 1 day.
Indicators of the concentration of IgA, IgM, IgG, IgE, and сcirculating immune complexes (CICs) in patients after severely injured trauma at the stages of treatment.
| IgA (mg/ml) | IgM (mg/ml) | IgG (mg/ml) | IgE (mg/ml) | CICs | |
|---|---|---|---|---|---|
| 1 day | 2.0+ (1.0–2.5) | 1.4+ (0.9–2.6) | 10.8+ (7.9–16.0) | 29,0+ (9,4–49,0) | 22,0-(15,5–56,0) |
| 3 day | 1.8+ (0.9–3.2) | 0.77+* (0.63–1.1) | 7.8* (6.2–15.0) | 33,0+ (8,0–55,4) | 32,0-(12,0–84,0) |
| 7 day | 2.2+ (1.4–3.6) | 1.32-(0.7–1.6) | 11.3-(7.8–17.8) | 61,0 ++* (22,0–219,0) | 53,0* (18,0–78,0) |
| 14 day | 2.4+* (1.9–4.0) | 1.5-(0.9–2.4) | 14.0* + (9.9–20.7) | 49,0++* (12,0–236,0) | 55,0* (22,0–94,0) |
| 21 day | 1.9+ (1.21–3.1) | 1.35-(1.03–1.9) | 12.0+ (8.6–16.9) | 46,0++* (11,0–184,0) | 65,0+* (49,0–104,0) |
| 30 day | 2.9+ (1.2–4.0) | 1.8+* (1.3–3.3) | 18.9 +* (11.0–24.11) | 24,0 ++* (11,0–107,0) | 47,5* (27,3–69,0) |
| 60 day | 1.93+ (1.3–3.5) | 1.5-(0.9–2.4) | 14.7+ (9.9–18.4) | 22,7+ (9,76–46,0) | 45,0-(29,0–58,0) |
| 90 day | 2.0+ (1.9–3.0) | 1.16-(0.8–1.7) | 13.6+ (9.2–15.3) | 20,0+ (13,0–43,0) | 45,0-(26,5–72,0) |
| Control group | 1.14 (0.75–2.0) | 1.26 (0.63–2.24) | 7.1 (5.6–14.7) | 12,6 (3,75–21,0) | 45,0 (29,0–53,0) |
Note: * (р ≤ 0.05), in comparison with the indicators of the preoperative period; + (р ≤ 0.05) and ++ (р ≤ 0.01), in comparison with the indicators of the control group; -, not statistically significant.
Indicators of innate immunity in patients after severely injured trauma.
| Period | СD3−СD16+ СD56+ | СD14+HLA-DR |
|---|---|---|
| 1 day | 14.1-(7.5–21.9) | 51.1+ (40.9–61.9) |
| 3 day | 8.1* (4.5–20.3) | 57.3+ (41.9–76.8) |
| 7 day | 7.4+* (4.6–12.1) | 61.1+* (44.4–71.5) |
| 14 day | 9.5* (5.5–13.6) | 66.4+* (56.2–77.3) |
| 21 day | 7.3* (5.6–14.8) | 74.9+* (61.9–81.3) |
| 30 day | 10.5* (6.2–13.0) | 76.6+* (73.3–81.3) |
| 60 day | 7.8* (6.2–11.6) | 76.2+* (70.3–85.6) |
| 90 day | 10.0-(7.6–19.0) | 75.6*+ (70.4–85.3) |
| Control group | 10.95 (8.58–14.3) | 91.6 (88.1–93.4) |
Note: * (р ≤ 0.05), in comparison with indicators of 1 day; + (р ≤ 0.05), in comparison with the indicators of the control group; -, not statistically significant.
Indicators of phagocytic activity of neutrophils in patients after severely injured trauma.
| Period | Phagocytic index | Phagocytic number | Spontaneous NBT test | Stimulated NBT test |
|---|---|---|---|---|
| 1 day | 67.0 (62.2–71.1) | 5.42+ (4.25–6.1) | 12.2++ (10.0–15.5) | 81.0+ (65.25–89.25+) |
| 3 day | 56.0 + (53.0–71.0) | 4.0*+ (3.5–4.5) | 16.0*++ (14.0–19.5) | 82.0+ (76.0–85.5) |
| 7 day | 78.0 (69.0–79.5) | 5.0*+ (4.5–5.0) | 20.0*++ (16.5–23.0) | 90.0*++ (86.0–92.0) |
| 14 day | 76.0 (68.0–78.0) | 5.0*+ (4.5–5.0) | 11.0*+ (9.0–11.5) | 82.0+ (81.0–83.0) |
| 21 day | 87.0* (81.5–88.5) | 8.0* (7.0–8.5) | 11.0+ (10.5–11.5) | 83.0+ (77.5–84.5) |
| 30 day | 76.0*+ (74.0–82.0) | 5.0*+ (5.0–5.5) | 12.0+ (10.5–12.5) | 86.0+ (78.0–87.5) |
| 60 day | 73.0*+ (70.0–79.0) | 5.0+ (5.0–6.0) | 10.0*+ (8.5–10.5) | 76.0+ (74.5–80.0) |
| 90 day | 71.0 (69.5–74.5) | 6.0+ (5.5–6.0) | 8.0*+ (7.5–9.0) | 66.0+ (63.5–69.0) |
| Control group | 71.0 (68.5–78.0) | 7.3 (6.8–8.0) | 6.0 (4.5 ÷ 7.0) | 57.0 (48.0 ÷ 62.3) |
Note: * (р ≤ 0.05), in comparison with indicators of 1 day; + (р ≤ 0.05) and ++ (р ≤ 0.01), in comparison with the indicators of the control group; NBT, nitroblue tetrazolium.
Fig. 2Immunoregulatory index (A), the circulating level of T helpers (Th) (B) and in B lymphocytes (C) in patients after severely injured trauma at the stages of treatment with a favorable course of the post-traumatic period and the development of complications.
Fig. 3The circulating level of interleukin 6 (IL-6) (A) and interleukin 10 (IL-10) (B) in patients after severely injured trauma at the stages of treatment with a favorable course of the post-traumatic period and the development of complications.
Fig. 4The circulating level of CD11 + CD18+(A) and natural killer (NK) cells (B) in patients after severely injured trauma at the stages of treatment with a favorable course of the post-traumatic period and the development of complications.
Fig. 5The value of a phagocytic number (A), spontaneous nitroblue tetrazolium (NBT) test (B), and neutrophil extracellular traps (NETs) (C) in patients after severely injured trauma at the stages of treatment with a favorable course of the post-traumatic period and the development of complications.
Indicators of innate immunity in patients after severely injured trauma with including purulent-inflammatory complications.
| Indicators | No complications | Pneumonia | Control group |
|---|---|---|---|
| Leukocytes, 109/L | 10.4*+ (8.4–12.2) | 12.6 ++ | 5.6 (3.2–8.4) |
| Monocytes, 109/L | 1.01*+ (0.85–1.21) | 0.78+ | 0.39 (0.22–0.5) |
| Neutrophils, 109/L | 7.63*+ (6.5–8.54) | 10.6++ | 3.28 (2.9–4.1) |
| Average cytochemical coefficient (ACC) | 2.6+ (2.5–2.8) | 2.6+ | 2.2 (2.0–2.4) |
| Spontaneous NBT test, % | 12.2+ (10.0–15.5) | 14.0+ | 6.0 (4.5 ÷ 7.0) |
| Stimulated NBT test, % | 81.0+ (65.25–89.25) | 80.5+ (73.75–86.25) | 54.0 (52.0–60.0) |
| Phagocytic index, % | 67.0 (62.2–71.1) | 61.4+ (51.2–66.3) | 71.0 (64.9–75.0) |
| Phagocytic number, % | 5.42+ (4.25–6.1) | 5.0+ (4.6–6.2) | 7.3 (6.2–7.7) |
| Number of active phagocytes (NAP), 109/L | 4.78*+ (3.2–6.5) | 6.3++ (4.2–8.5) | 2.3 (1.9–2.5) |
| Absolute phagocytic index (API),109/L | 38.8*+ (37.5–52.2) | 53.5+ (45.2–79.5) | 24.0 (20.0–35.5) |
Note: * (р ≤ 0.05), in comparison with the indicators of the patients group with pneumonia; + (р ≤ 0.05) and ++ (р ≤ 0.01), in comparison with the indicators of the control group; NBT, nitroblue tetrazolium.
Fig. 6The circulating level of CD14+HLA-DR (A) and natural killer (NK) cells (B), and the value of neutrophil extracellular traps (NETs) (C) in patients after severely injured trauma at the stages of treatment with a favorable course of the post-traumatic period and the development of pneumonia. Statistical significance (*p ≤ 0.05 and **p ≤ 0.01). Note: The indicators of patients without complications and with pneumonia were compared with the control group.